Telormedix joins TIMER research programme
EU and Brazil invest in project to fight inflammatory diseases
Swiss biopharmaceutical firm Telormedix has been elected as a member of the Targeting novel mechanisms of resolution in inflammation (TIMER) collaborative research programme.
Co-funded with €3m from the EU to establish collaboration with Brazil, the project comprises a team of European universities and research institutions alongside top Brazilian groups.
Telormedix and Merck Serono are both participating in the project to promote translational research.
Telormedix will primarily draw on its expertise in the field of modulators of Toll-like Receptors (TLRs), which play a key role in inflammatory diseases.
TIMER was launched on 1 January to accelerate the development of novel strategies to fight inflammation. Scientists from nine research partners in four European countries and three research partners in Brazil are collaborating in the programme.
‘This is a unique opportunity for European scientists to strengthen ties with Brazilian colleagues addressing central issues related to inflammation, of broad potential in immune-based pathologies. The project will capitalise on productive interactions. The availability of natural resources, models of diseases, original paradigms and molecular approaches will be conducive to synergistic interactions,’ commented Alberto Mantovani, coordinator of TIMER and director of the Istituto Clinico Humanitas in Milan, Italy.
